Cargando…
P53 suppresses ribonucleotide reductase via inhibiting mTORC1
Balanced deoxyribonucleotides pools are essential for cell survival and genome stability. Ribonucleotide reductase is the rate-limiting enzyme for the production of deoxyribonucleotides. We report here that p53 suppresses ribonucleotide reductase subunit 1 (RRM1) and 2 (RRM2) via inhibiting mammalia...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522210/ https://www.ncbi.nlm.nih.gov/pubmed/28507282 http://dx.doi.org/10.18632/oncotarget.17440 |
_version_ | 1783252123322941440 |
---|---|
author | He, Zhengfu Hu, Xing Liu, Weijin Dorrance, Adrienne Garzon, Ramiro Houghton, Peter J. Shen, Changxian |
author_facet | He, Zhengfu Hu, Xing Liu, Weijin Dorrance, Adrienne Garzon, Ramiro Houghton, Peter J. Shen, Changxian |
author_sort | He, Zhengfu |
collection | PubMed |
description | Balanced deoxyribonucleotides pools are essential for cell survival and genome stability. Ribonucleotide reductase is the rate-limiting enzyme for the production of deoxyribonucleotides. We report here that p53 suppresses ribonucleotide reductase subunit 1 (RRM1) and 2 (RRM2) via inhibiting mammalian target of rapamycin complex 1 (mTORC1). In vitro, cancer cell lines and mouse embryonic fibroblast cells were treated with different concentrations of pharmacological inhibitors for different times. In vivo, rhabdomyosarcoma Rh30 cell tumor-bearing mice were treated with rapamycin or AZD8055. Protein levels and phosphorylation status were assessed by immunoblotting and mRNA levels were determined by real time RT-PCR. Pharmacological inhibition of mTORC1 with rapamycin, mTOR kinase with AZD8055 or protein kinase B with MK2206 resulted in decrease of RRM1 and RRM2 in Rh30 cells both in vitro and in mouse tumor xenografts. Moreover, eukaryotic translational initiation factor 4E-binding proteins 1 and 2 double knockout mouse embryonic fibroblast cells demonstrated an elevation of RRM1 and RRM2. Furthermore, down-regulation of mTOR-protein kinase B signaling or cyclin dependent kinase 4 led to decrease of RRM1 and RRM2 mRNAs. In addition, TP53 mutant cancer cells had elevation of RRM1 and RRM2, which was reduced by rapamycin. Importantly, human double minute 2 inhibitor nutlin-3 decreased RRM1 and RRM2 in TP53 wild type rhabdomyosarcoma Rh18 but not in TP53 mutated Rh30 cells. Our data demonstrated that mTOR enhances the cap-dependent protein translation and gene transcription of RRM1 and RRM2. Our findings might provide an additional mechanism by which p53 maintains genome stability. |
format | Online Article Text |
id | pubmed-5522210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-55222102017-08-21 P53 suppresses ribonucleotide reductase via inhibiting mTORC1 He, Zhengfu Hu, Xing Liu, Weijin Dorrance, Adrienne Garzon, Ramiro Houghton, Peter J. Shen, Changxian Oncotarget Research Paper Balanced deoxyribonucleotides pools are essential for cell survival and genome stability. Ribonucleotide reductase is the rate-limiting enzyme for the production of deoxyribonucleotides. We report here that p53 suppresses ribonucleotide reductase subunit 1 (RRM1) and 2 (RRM2) via inhibiting mammalian target of rapamycin complex 1 (mTORC1). In vitro, cancer cell lines and mouse embryonic fibroblast cells were treated with different concentrations of pharmacological inhibitors for different times. In vivo, rhabdomyosarcoma Rh30 cell tumor-bearing mice were treated with rapamycin or AZD8055. Protein levels and phosphorylation status were assessed by immunoblotting and mRNA levels were determined by real time RT-PCR. Pharmacological inhibition of mTORC1 with rapamycin, mTOR kinase with AZD8055 or protein kinase B with MK2206 resulted in decrease of RRM1 and RRM2 in Rh30 cells both in vitro and in mouse tumor xenografts. Moreover, eukaryotic translational initiation factor 4E-binding proteins 1 and 2 double knockout mouse embryonic fibroblast cells demonstrated an elevation of RRM1 and RRM2. Furthermore, down-regulation of mTOR-protein kinase B signaling or cyclin dependent kinase 4 led to decrease of RRM1 and RRM2 mRNAs. In addition, TP53 mutant cancer cells had elevation of RRM1 and RRM2, which was reduced by rapamycin. Importantly, human double minute 2 inhibitor nutlin-3 decreased RRM1 and RRM2 in TP53 wild type rhabdomyosarcoma Rh18 but not in TP53 mutated Rh30 cells. Our data demonstrated that mTOR enhances the cap-dependent protein translation and gene transcription of RRM1 and RRM2. Our findings might provide an additional mechanism by which p53 maintains genome stability. Impact Journals LLC 2017-04-26 /pmc/articles/PMC5522210/ /pubmed/28507282 http://dx.doi.org/10.18632/oncotarget.17440 Text en Copyright: © 2017 He et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper He, Zhengfu Hu, Xing Liu, Weijin Dorrance, Adrienne Garzon, Ramiro Houghton, Peter J. Shen, Changxian P53 suppresses ribonucleotide reductase via inhibiting mTORC1 |
title | P53 suppresses ribonucleotide reductase via inhibiting mTORC1 |
title_full | P53 suppresses ribonucleotide reductase via inhibiting mTORC1 |
title_fullStr | P53 suppresses ribonucleotide reductase via inhibiting mTORC1 |
title_full_unstemmed | P53 suppresses ribonucleotide reductase via inhibiting mTORC1 |
title_short | P53 suppresses ribonucleotide reductase via inhibiting mTORC1 |
title_sort | p53 suppresses ribonucleotide reductase via inhibiting mtorc1 |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522210/ https://www.ncbi.nlm.nih.gov/pubmed/28507282 http://dx.doi.org/10.18632/oncotarget.17440 |
work_keys_str_mv | AT hezhengfu p53suppressesribonucleotidereductaseviainhibitingmtorc1 AT huxing p53suppressesribonucleotidereductaseviainhibitingmtorc1 AT liuweijin p53suppressesribonucleotidereductaseviainhibitingmtorc1 AT dorranceadrienne p53suppressesribonucleotidereductaseviainhibitingmtorc1 AT garzonramiro p53suppressesribonucleotidereductaseviainhibitingmtorc1 AT houghtonpeterj p53suppressesribonucleotidereductaseviainhibitingmtorc1 AT shenchangxian p53suppressesribonucleotidereductaseviainhibitingmtorc1 |